利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.016 秒)

    Control of cancer growth through the interaction of [Met.sup.5 ]-enkephalin and the zeta (.zeta.) receptor
    3.
    发明授权
    Control of cancer growth through the interaction of [Met.sup.5 ]-enkephalin and the zeta (.zeta.) receptor 失效
    通过[Met5] - 脑啡肽和ζ（ζ）受体的相互作用控制癌症生长

    公开(公告)号：US06136780A

    公开(公告)日：2000-10-24

    申请号：US827481

    申请日：1997-03-27

    申请人： Ian S. Zagon ,  Patricia J. McLaughlin

    发明人： Ian S. Zagon ,  Patricia J. McLaughlin

    IPC分类号： A61K38/22 ,  A61K31/00 ,  A61K31/485 ,  A61K33/24 ,  A61K38/33 ,  A61K45/06 ,  A61P35/00 ,  A61K38/00

    CPC分类号： A61K45/06 ,  A61K31/485 ,  A61K33/24 ,  A61K38/33

    摘要： The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met.sup.5 ]-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (.zeta.) opioid receptor through endogenous [Met.sup.5 ]-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example.

    摘要翻译： 本发明涉及特别是胃肠癌的癌症的治疗和预防。 更具体地，本发明描述了纳曲酮，纳洛酮和五肽生长因子[Met5] - 脑啡肽抑制和阻止癌症生长的用途。 已经发现这种效率是通过内源[Met5] - 脑啡肽功能操作ζ（ζ）阿片受体的结果。 已确定该受体存在于生长中的癌症例如胰腺癌和结肠癌中。

    Opioid growth factor receptors
    5.
    发明授权
    Opioid growth factor receptors 有权
    阿片样生长因子受体

    公开(公告)号：US07576180B2

    公开(公告)日：2009-08-18

    申请号：US11890621

    申请日：2007-08-07

    申请人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Michael F. Verderame

    发明人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Michael F. Verderame

    IPC分类号： C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  A01N37/18 ,  A61K38/00

    CPC分类号： C12N15/1138 ,  A61K38/00 ,  C07K14/71 ,  C07K16/28 ,  C12N2310/11 ,  C12N2310/315

    摘要： This invention relates to novel nucleic acid molecules coding for opioid growth factor receptors. In particular, the present invention provides isolated nucleic acid molecules coding for human and rat OGF receptors. Antisense molecules, expression vectors and host cells, isolated proteins encoded by such nucleic acid molecules, antibodies directed against such proteins, as well as pharmaceutical compositions derived therefrom are also included. The invention further provides methods of modulating cell growth by using the isolated nucleic acid molecules, the antisense molecules and the antibodies directed against the encoded proteins.

    摘要翻译： 本发明涉及编码阿片类生长因子受体的新型核酸分子。 特别地，本发明提供编码人和大鼠OGF受体的分离的核酸分子。 还包括反义分子，表达载体和宿主细胞，由这种核酸分子编码的分离的蛋白质，针对这种蛋白质的抗体，以及由其衍生的药物组合物。 本发明还提供了通过使用分离的核酸分子，反义分子和针对编码的蛋白质的抗体来调节细胞生长的方法。

    Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
    9.
    发明授权
    Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists 有权
    用阿片样物质拮抗剂治疗肠道炎症和溃疡性疾病

    公开(公告)号：US07879870B2

    公开(公告)日：2011-02-01

    申请号：US11735548

    申请日：2007-04-16

    申请人： Jill P. Smith ,  Ian S. Zagon ,  Moshe Rogosnitzky

    发明人： Jill P. Smith ,  Ian S. Zagon ,  Moshe Rogosnitzky

    IPC分类号： A61K31/485

    CPC分类号： A61K31/4748 ,  A61K31/485

    摘要： Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with a therapeutically effective dose less than 50 mg. of opioid antagonists (e.g., naltrexone, nalmefene or naloxone) are disclosed. An embodiment of the invention includes a method of pharmaceutical treatment comprising orally administering to a human subject having Crohn's disease or ulcerative colitis a therapeutic pharmaceutical composition once per day in the evening or at bedtime, wherein the pharmaceutical composition comprises form about 3 mg to about 4.5 mg of naltrexone, nalmefene, naloxone, or a hydrochloride salt thereof in an immediate release solid dosage formulation.

    摘要翻译： 用于治疗肠道炎症和溃疡性疾病（例如克罗恩病和溃疡性结肠炎）的治疗有效剂量小于50mg的方法。 的阿片样物质拮抗剂（例如纳曲酮，纳美芬或纳洛酮）。 本发明的一个实施方案包括一种药物治疗方法，其包括在晚上或在睡前每天一次口服给予具有克罗恩病或溃疡性结肠炎的人受试者治疗药物组合物，其中所述药物组合物包含约3mg至约4.5 毫克纳曲酮，纳美芬，纳洛酮或其盐酸盐。

    Cyclin-dependent kinase inhibitors as targets for opiod growth factor treatment
    10.
    发明申请
    Cyclin-dependent kinase inhibitors as targets for opiod growth factor treatment 有权
    细胞周期蛋白依赖性激酶抑制剂作为阿片类生长因子治疗的靶标

    公开(公告)号：US20080146512A1

    公开(公告)日：2008-06-19

    申请号：US11901770

    申请日：2007-09-19

    申请人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Michael F. Verderame

    发明人： Ian S. Zagon ,  Patricia J. McLaughlin ,  Michael F. Verderame

    IPC分类号： A61K38/08 ,  C12Q1/48 ,  G01N33/48 ,  A61P17/02

    CPC分类号： G01N33/574 ,  A61K38/005 ,  A61K38/33 ,  G01N33/68 ,  G01N33/6842 ,  G01N2333/475 ,  G01N2333/91215 ,  G01N2800/52

    摘要： The present invention provides methods of cell cycle control by administering opioid growth factor (OGF), which activates opioid growth factor receptor (OGFr) signaling. Particularly, the present invention provides a method for monitoring OGF modulation or treatment of a cell proliferation or growth related condition in a subject by assessing the level of the cyclin dependent kinase inhibitor (CKI) relevant or corresponding to the condition. The present invention also provides a method for screening the eligibility of a subject for OGF modulation or treatment by assessing the level of OGF receptor (OGFr) and the relevant CKI. A method for enhancing the efficacy of OGF therapy by increasing the level of the relevant CKI and/or OGFr is also provided.

    摘要翻译： 本发明通过施用激活阿片样物质生长因子受体（OGFr）信号传导的阿片样生长因子（OGF）来提供细胞周期控制的方法。 特别地，本发明提供了通过评估与病症相关或相应的细胞周期蛋白依赖性激酶抑制剂（CKI）的水平来监测受试者的OGF调节或治疗细胞增殖或生长相关状态的方法。 本发明还提供了通过评估OGF受体（OGFr）水平和相关CKI来筛选受试者对OGF调节或治疗的资格的方法。 还提供了通过增加相关CKI和/或OGFr的水平来提高OGF治疗功效的方法。